Knowledge graph · Drug
Tirbanibulin
small molecule
- Identifier
- CI-DRUG-00000592
- Entity page
- /drug/tirbanibulin ↗
- Edges
- 19
- Neighbours
- 5 cancers1 genes9 trials2 approvals
- Drawn
- 17 of 17 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Tirbanibulin approved for …APPROVED_FORderived2 of 2 | ||||||||
| → approved for | FDA · US · 2024Efficacy supplement 2024-06-07 (see label) FDA (US) · approved · 2024-06-07 · Efficacy supplement 2024-06-07 (see label) | — | approved | not mapped | 1 | Regulatory | openfda | open ↗ |
| → approved for | FDA · US · 2020KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. ( 1 ) | |||||||